Corroborating their known pleiotropic effects, preclinical studies have demonstrated that PCSK9 inhibition synergistically enhances immunotherapy’s anti-tumor effects through LDL-receptor-independent pathways [76,77]. Here, LDLR is linked to neoplasm.